The global preimplantation genetic screening (PGS) technology market is experiencing transformative advancements in prenatal screening and diagnosis of chromosomal abnormalities. Cutting-edge technologies have revolutionized in vitro fertilization (IVF) processes by incorporating non-invasive cell-free fetal DNA-based detection and carrier screening panels into prenatal care. PGS technology emerges as a significant market driver, enabling early detection of congenital disorders during the initial stages of the IVF workflow. This facilitates the reduction of inherited chromosomal abnormalities in fetuses, underscoring the pivotal role of PGS in enhancing the success and safety of assisted reproduction.
According to Data Bridge Market Research, the Global Preimplantation Genetic Screening (PGS) Technology Market was USD 552.50 million in 2021, is expected to reach USD 1,228.09 million by 2029, and is expected to undergo a CAGR of 10.50% during the forecast period 2022 to 2029.
“Rising number of fertility clinics globally facilitate market growth”
The rising number of fertility clinics globally serves as a significant driver for the preimplantation genetic screening (PGS) technology market. As the demand for assisted reproductive technologies such as in vitro fertilization (IVF) continues to surge, the establishment of more fertility clinics becomes essential to accommodate this growing need. These clinics offer PGS as a valuable tool to enhance the success rates of IVF procedures by selecting genetically healthy embryos. This expansion of fertility clinics amplifies the adoption of PGS technology, fostering its market growth and accessibility for couples seeking successful pregnancies.
What restraints the growth of the global preimplantation genetic screening (PGS) technology market?
“High cost associated with preimplantation genetic screening (PGS) technology”
The high cost associated with preimplantation genetic screening (PGS) technology serves as a significant restraint in the global market. The intricate process of genetic screening involves advanced technologies and specialized expertise, resulting in substantial expenses for couples seeking these services. The elevated costs can create a barrier for many individuals, limiting their access to PGS procedures. This financial challenge can deter potential beneficiaries from pursuing PGS, thereby impeding the broader adoption of this technology and hindering its realization of its full potential in improving assisted reproductive outcomes.
Segmentation: Global Preimplantation Genetic Screening (PGS) Technology Market
The preimplantation genetic screening (PGS) technology market is segmented on the basis of procedure type, technology, product and services, test type, application, and end user.
- 根據程序類型，植入前基因篩檢 (PGS) 技術市場分為植入前基因篩檢和植入前基因診斷。
- 根據技術，植入前遺傳篩檢 (PGS) 技術市場細分為下一代定序、聚合酶鍊式反應、螢光原位雜交、比較基因組雜交和單核苷酸多態性。
- 根據產品和服務，植入前基因篩檢（PGS）技術市場細分為試劑和耗材、儀器、軟體和服務。
- 根據最終用戶，植入前基因篩檢 (PGS) 技術市場分為婦產中心和生育診所、醫院、診斷實驗室、服務提供者、研究實驗室和學術機構。
- 根據測試類型，植入前基因篩檢 (PGS) 技術市場分為染色體異常、X 連鎖疾病、胚胎測試、非整倍體篩檢、HLA 分型和其他 PGT 類型。
- 根據應用，植入前基因篩檢 (PGS) 技術市場細分為用於幹細胞治療的胚胎 HLA 分型、IVF 預後、晚發性遺傳疾病、遺傳性疾病等。
區域洞察：北美主導全球植入前基因篩檢 (PGS) 技術市場
北美在植入前基因篩檢（PGS）技術市場佔據主導地位。這可以歸因於該地區晚期懷孕的趨勢上升，導致對體外受精（IVF）等生育治療的需求增加。該地區完善的醫療保健基礎設施和先進的生殖技術進一步增強了其在 PGS 技術領域的突出地位。
亞太地區植入前基因篩檢 (PGS) 技術市場可望大幅成長。預計 2022 年至 2029 年期間該地區將在多種因素的推動下快速擴張。該地區正在經歷技術進步的激增以及植入前基因檢測 (PGT) 工作流程的採用。這種日益增長的採用反映了該地區致力於利用尖端技術來改善生殖結果的決心。
要了解有關該研究的更多信息，請訪問：https://www.databridgemarketresearch.com/reports/global-preimplantation-genetic-screening-pgs-technology-market
全球植入前基因篩檢 (PGS) 技術市場的主要參與者包括：
- Illumina公司（美國）
- 賽默飛世爾科技公司（美國）
- 安捷倫科技公司（美國）
- PerkinElmer公司（美國）
- CooperSurgical, Inc.（美國）
- 北京華大基因（BGI）（中國）
- 雅培（美國）
- 西門子（德國）
- QIAGEN（德國）
以上是報告中涵蓋的關鍵參與者，要了解更多全球植入前基因篩檢 (PGS) 技術市場公司聯絡資訊的詳盡列表，請造訪 https://www.databridgemarketresearch.com/contact
研究方法：全球植入前基因篩檢（PGS）技術市場
資料收集和基準年分析是使用具有大樣本量的資料收集模組完成的。使用市場統計和相干模型來分析和估計市場數據。此外，市場佔有率分析和關鍵趨勢分析是市場報告中的主要成功因素。 DBMR 研究團隊使用的關鍵研究方法是資料三角測量，其中涉及資料探勘、資料變數對市場的影響分析以及初步（產業專家）驗證。除此之外，資料模型還包括供應商定位網格、市場時間軸分析、市場概覽和指南、公司定位網格、公司市場份額分析、測量標準、全球與區域以及供應商份額分析。如有進一步疑問，請要求分析師致電。
